BACKGROUND: Higher intake of monounsaturated fat may raise high-density lipoprotein (HDL) cholesterol without raising low-density lipoprotein (LDL) cholesterol. We tested whether increasing the monounsaturated fat content of a diet proven effective for lowering LDL cholesterol (dietary portfolio) also modified other risk factors for cardiovascular disease, specifically by increasing HDL cholesterol, lowering serum triglyceride and further reducing the ratio of total to HDL cholesterol. METHODS:Twenty-four patients with hyperlipidemia consumed a therapeutic diet very low in saturated fat for one month and were then randomly assigned to a dietary portfolio low or high in monounsaturated fatty acid for another month. We supplied participants' food for the two-month period. Calorie intake was based on Harris-Benedict estimates for energy requirements. RESULTS: For patients who consumed the dietary portfolio high in monounsaturated fat, HDL cholesterol rose, whereas for those consuming the dietary portfolio low in monounsaturated fat, HDL cholesterol did not change. The 12.5% treatment difference was significant (0.12 mmol/L, 95% confidence interval [CI] 0.05 to 0.21, p = 0.003). The ratio of total to HDL cholesterol was reduced by 6.5% with the diet high in monounsaturated fat relative to the diet low in monounsaturated fat (-0.28, 95% CI -0.59 to -0.04, p = 0.025). Patients consuming the diet high in monounsaturated fat also had significantly higher concentrations of apolipoprotein AI, and their C-reactive protein was significantly lower. No treatment differences were seen for triglycerides, other lipids or body weight, and mean weight loss was similar for the diets high in monounsaturated fat (-0.8 kg) and low in monounsaturated fat (-1.2 kg). INTERPRETATION: Monounsaturated fat increased the effectiveness of a cholesterol-lowering dietary portfolio, despite statin-like reductions in LDL cholesterol. The potential benefits for cardiovascular risk were achieved through increases in HDL cholesterol, further reductions in the ratio of total to HDL cholesterol and reductions in C-reactive protein. (ClinicalTrials.gov trial register no. NCT00430430.).
RCT Entities:
BACKGROUND: Higher intake of monounsaturated fat may raise high-density lipoprotein (HDL) cholesterol without raising low-density lipoprotein (LDL) cholesterol. We tested whether increasing the monounsaturated fat content of a diet proven effective for lowering LDL cholesterol (dietary portfolio) also modified other risk factors for cardiovascular disease, specifically by increasing HDL cholesterol, lowering serum triglyceride and further reducing the ratio of total to HDL cholesterol. METHODS: Twenty-four patients with hyperlipidemia consumed a therapeutic diet very low in saturated fat for one month and were then randomly assigned to a dietary portfolio low or high in monounsaturated fatty acid for another month. We supplied participants' food for the two-month period. Calorie intake was based on Harris-Benedict estimates for energy requirements. RESULTS: For patients who consumed the dietary portfolio high in monounsaturated fat, HDL cholesterol rose, whereas for those consuming the dietary portfolio low in monounsaturated fat, HDL cholesterol did not change. The 12.5% treatment difference was significant (0.12 mmol/L, 95% confidence interval [CI] 0.05 to 0.21, p = 0.003). The ratio of total to HDL cholesterol was reduced by 6.5% with the diet high in monounsaturated fat relative to the diet low in monounsaturated fat (-0.28, 95% CI -0.59 to -0.04, p = 0.025). Patients consuming the diet high in monounsaturated fat also had significantly higher concentrations of apolipoprotein AI, and their C-reactive protein was significantly lower. No treatment differences were seen for triglycerides, other lipids or body weight, and mean weight loss was similar for the diets high in monounsaturated fat (-0.8 kg) and low in monounsaturated fat (-1.2 kg). INTERPRETATION:Monounsaturated fat increased the effectiveness of a cholesterol-lowering dietary portfolio, despite statin-like reductions in LDL cholesterol. The potential benefits for cardiovascular risk were achieved through increases in HDL cholesterol, further reductions in the ratio of total to HDL cholesterol and reductions in C-reactive protein. (ClinicalTrials.gov trial register no. NCT00430430.).
Authors: V Manninen; L Tenkanen; P Koskinen; J K Huttunen; M Mänttäri; O P Heinonen; M H Frick Journal: Circulation Date: 1992-01 Impact factor: 29.690
Authors: B E Ainsworth; W L Haskell; A S Leon; D R Jacobs; H J Montoye; J F Sallis; R S Paffenbarger Journal: Med Sci Sports Exerc Date: 1993-01 Impact factor: 5.411
Authors: Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh Journal: JAMA Date: 2009-11-11 Impact factor: 56.272
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Circulation Date: 2004-07-13 Impact factor: 29.690
Authors: David J A Jenkins; Cyril W C Kendall; Augustine Marchie; Dorothea A Faulkner; Julia M W Wong; Russell de Souza; Azadeh Emam; Tina L Parker; Edward Vidgen; Karen G Lapsley; Elke A Trautwein; Robert G Josse; Lawrence A Leiter; Philip W Connelly Journal: JAMA Date: 2003-07-23 Impact factor: 56.272
Authors: D J Gordon; J L Probstfield; R J Garrison; J D Neaton; W P Castelli; J D Knoke; D R Jacobs; S Bangdiwala; H A Tyroler Journal: Circulation Date: 1989-01 Impact factor: 29.690
Authors: Amol B Tayade; Priyanka Dhar; Jatinder Kumar; Manu Sharma; Om P Chaurasia; Ravi B Srivastava Journal: J Food Sci Technol Date: 2017-01-30 Impact factor: 2.701
Authors: Paraskevi Massara; Andreea Zurbau; Andrea J Glenn; Laura Chiavaroli; Tauseef A Khan; Effie Viguiliouk; Sonia Blanco Mejia; Elena M Comelli; Victoria Chen; Ursula Schwab; Ulf Risérus; Matti Uusitupa; Anne-Marie Aas; Kjeld Hermansen; Inga Thorsdottir; Dario Rahelić; Hana Kahleová; Jordi Salas-Salvadó; Cyril W C Kendall; John L Sievenpiper Journal: Diabetologia Date: 2022-08-26 Impact factor: 10.460
Authors: Seth J Baum; Penny M Kris-Etherton; Walter C Willett; Alice H Lichtenstein; Lawrence L Rudel; Kevin C Maki; Jay Whelan; Christopher E Ramsden; Robert C Block Journal: J Clin Lipidol Date: 2012-04-13 Impact factor: 5.365
Authors: David J A Jenkins; Cyril W C Kendall; Monica S Banach; Korbua Srichaikul; Edward Vidgen; Sandy Mitchell; Tina Parker; Stephanie Nishi; Balachandran Bashyam; Russell de Souza; Christopher Ireland; Robert G Josse Journal: Diabetes Care Date: 2011-06-29 Impact factor: 19.112